These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 8390270)

  • 1. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.
    Youdim MB; Riederer P
    J Neural Transm Gen Sect; 1993; 91(2-3):181-95. PubMed ID: 8390270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
    Finberg JP
    Pharmacol Ther; 2014 Aug; 143(2):133-52. PubMed ID: 24607445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
    Gal S; Abassi ZA; Youdim MB
    Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
    Finberg JPM
    J Neural Transm (Vienna); 2019 Apr; 126(4):433-448. PubMed ID: 30386930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monoamine oxidase as a target for drug action].
    Drozak J; Kozłowski M
    Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission.
    Napolitano A; Cesura AM; Da Prada M
    J Neural Transm Suppl; 1995; 45():35-45. PubMed ID: 8748607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitory monoamine oxidases of the new generation].
    Nowakowska E; Chodera A
    Pol Merkur Lekarski; 1997 Jul; 3(13):1-4. PubMed ID: 9432289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
    Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
    Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
    Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
    J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine oxidase B inhibition and the "cheese effect".
    Youdim MB; Finberg JP
    J Neural Transm Suppl; 1987; 25():27-33. PubMed ID: 3480939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
    Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain.
    Fagervall I; Ross SB
    J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.